minerva-surgicalMinerva Surgical (Nasdaq:UTRS) announced that it appointed Todd Usen to replace retiring President and CEO David Clapper.

Clapper served as president and CEO of the abnormal uterine bleeding (AUB) treatment developer since 2011. Minerva selected Former Activ Surgical CEO Todd Usen to take over those roles and become a member of the board, effective Jan. 2, 2023. Usen announced his departure from Activ earlier this month.

To ensure a smooth transition, Clapper plans to serve in his role through Usen’s first day, according to a news release. He also entered into a consulting agreement for 12 months following his retirement.

“It’s been a great privilege to collaborate with our incredible team to serve Minerva Surgical’s stockholders, customers, and employees, and I am so proud of what we’ve accomplished together,” said Clapper. “I have served over eleven years as CEO, and I feel this is the right time for me to step aside and start a new chapter in my life. Minerva Surgical is in a great operational position and is led by an experienced management team. I have the utmost confidence in Todd to lead Minerva Surgical into the future and fulfill the mission to meet the uterine health needs of women.”

About new Minerva Surgical CEO Todd Usen

Usen spent four years as CEO at Activ Surgical. For three years before that, he served as president of Olympus’ Medical Systems Group.

Other roles include president and vice president positions at Smith+Nephew, as well as a VP and director slot at Boston Scientific.

Usen said earlier this month that he left the CEO role at Activ Surgical to take on his next challenge, according to a post on LinkedIn.

“I am honored to join Minerva Surgical and look forward to working with the entire organization to continue driving value for all stakeholders, but most importantly women all over the world who experience heavy bleeding, leading to unnecessary hysterectomies,” said Usen. “With the most convincing clinical data in the market, a strong commercial footprint and the recently announced financing, I believe that Minerva Surgical is poised to scale our growth and deliver best-in-class surgical solutions to better serve the compelling unmet needs in women’s health today.”